Select Language
IL-2 R alpha
IL-2 R alpha Overview
| English Name | Interleukin-2 receptor alpha chain | Approved Drugs | 3 |
| Drugs in Clinical Trials | 16 | Target Synonym | TAC antigen，p55，IL2-RA，Interleukin-2 receptor subunit alpha，IL-2-RA，IL-2R subunit alpha，IL2RA，Interleukin 2 Receptor Subunit Alpha，Interleukin 2 Receptor， Alpha，IL-2 Receptor Subunit Alpha，Insulin-Dependent Diabetes Mellitus 10，CD25 Antigen，IDDM10，IMD41，TCGFR，CD25，Interleukin-2 Receptor alpha Subunit，IL-2R alpha |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-2 receptor alpha chain |
| Target Synonym | TAC antigen，p55，IL2-RA，Interleukin-2 receptor subunit alpha，IL-2-RA，IL-2R subunit alpha，IL2RA，Interleukin 2 Receptor Subunit Alpha，Interleukin 2 Receptor， Alpha，IL-2 Receptor Subunit Alpha，Insulin-Dependent Diabetes Mellitus 10，CD25 Antigen，IDDM10，IMD41，TCGFR，CD25，Interleukin-2 Receptor alpha Subunit，IL-2R alpha |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 16 |
| Highest Development Stage | Approved |
IL-2 R alpha Product List
- Product Category
Protein (11)
- Product Status
Launched (11)
- Species
Human (4)Mouse (2)Canine (1)Cynomolgus (2)Rhesus macaque (1)Rat (1)
- Tag
Fc Tag (1)His Tag (6)His Tag & Avi Tag (3)Fc Tag & Avi Tag (1)
- Conjugate
Unconjugated (7)Biotin-labeled (4)
Total: 11
- 1
- 2
IL-2 R alpha Synonyms
IL2RA,CD25,p55,IL2-RA,IL-2-RA
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| CD25 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
| LMB-2 | LMB-2; LMB-2a | Phase 2 Clinical | National Cancer Institute | Leukemia; Leukemia, Hairy Cell; Leukemia, T-Cell; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Skin Melanoma; Skin Neoplasms | Details |
| Nemvaleukin alfa | RDB-1419; RDB-1450; ALKS-4230 | Phase 2 Clinical | Alkermes Plc | Fallopian Tube Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Adc Therapeutics Sa, Genmab A/S | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Melanoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| 90Y-HAT (NCI) | Phase 2 Clinical | National Cancer Institute | Hodgkin Disease; Lymphoma, Non-Hodgkin | Details | |
| Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Graft vs Host Disease | Details | |
| 90Y Basiliximab | Phase 2 Clinical | City Of Hope National Medical Center | Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| PT-101 | PT-101; MK-6194; PT101 | Phase 1 Clinical | Pandion Therapeutics | Colitis, Ulcerative; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Vitiligo | Details |
| Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Celiac Disease; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphoid; Paraparesis, Tropical Spastic | Details |
| BA-1106 | TS-1904; BA-1106; RR-102 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| XmAb-564 | XmAb-564; XmAb564; XmAb-27564 | Phase 1 Clinical | Xencor Inc | Autoimmune Diseases; Dermatitis, Atopic; Psoriasis | Details |
| PF-08046032 | PF-08046032 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| 9MW-3911 | 9MW3911; 9MW-3911 | Phase 1 Clinical | Nanjing Nuo Aixin Biotechnology Co Ltd | Neoplasms | Details |
| In 111-DOTA-Basiliximab | Phase 1 Clinical | City Of Hope National Medical Center | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| BMS-986326 | BMS-986326 | Phase 1 Clinical | Bristol-Myers Squibb Company | Dermatitis, Atopic; Lupus Vulgaris | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
| Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Rejection of organ transplantation | F. Hoffmann-La Roche Ag | 1997-12-10 | Anemia, Aplastic; Anemia, Diamond-Blackfan; Arthritis, Juvenile; Asthma; Behcet Syndrome; Breast Neoplasms; Carcinoma, Ductal; Colitis, Ulcerative; Diabetes Mellitus, Type 1; Gastrointestinal Diseases; Granulomatosis with Polyangiitis; HIV Infections; HTLV-I Infections; Inflammatory Bowel Diseases; Iritis; Leukemia; Leukemia, T-Cell; Lymphoma; Melanoma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myelodysplastic Syndromes; Psoriasis; Radiation Injuries; Red-Cell Aplasia, Pure; Rejection in heart transplantation; Rejection of organ transplantation; Retinal Diseases; Thrombocytopenia; Uveitis; Uveitis, Anterior | Details |
| Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | United States | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Anemia, Aplastic; Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Emphysema; Hemoglobinuria, Paroxysmal; Hodgkin Disease; Keratoplasty rejection; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Pulmonary Disease, Chronic Obstructive; Rejection of renal transplantation; Rejection of organ transplantation; Uveitis | Details |
Product Reviews
E***n2023-04-08
1People LikeYeast cells expressing and displaying different IL2 variants were incubated 1h in the presence of CD25 protein with His tag (Human Il-2 R alpha Acrobiosystems #ILA-H52H9) at a final concentration of 4µg/ml. Next, cells were washed and incubated with a mouse Anti-His-PE. The yeast cells were washed and were analyzed using FACS. We observed detectable amounts of fluorescence bound to yeast cells displaying specific IL2 variants confirming that CD25 could bind to certain constructs and providing evidence that certain IL2 variants were correctly folded.- 1***22022-08-03 0People LikeI purchased the company’s mouse-derived CD25 protein for the evaluation of CD25 antibody affinity. It achieved a high sensitivity detection with a small amount! Very satisfied, will come back to purchase more if needed!
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland